Systematic Discovery of Molecular Glues Targets Protein Degradation in Leukemia

Why It Matters

The approach transforms molecular‑glue discovery into a reproducible, scalable process, offering new therapeutic avenues for cancers and other diseases driven by traditionally undruggable targets.

Key Takeaways

• High-throughput ligand diversification enables rapid molecular glue discovery
• ENL degradation suppresses growth of leukemia cells
• Cellular screening bypasses need for protein purification
• Cooperative binding creates selective ubiquitin ligase recruitment
• Approach could expand druggable proteome for undruggable targets

Pulse Analysis

Molecular glues have emerged as a powerful class of therapeutics that co‑opt the cell’s ubiquitin‑proteasome system to eliminate disease‑causing proteins. Historically, their discovery relied on serendipity, limiting the ability to target the vast majority of proteins deemed "undruggable." By integrating combinatorial chemistry with functional readouts in live cells, the new platform sidesteps the bottleneck of protein purification and accelerates the identification of compounds that can forge novel protein‑protein interfaces.

The AITHYRA team applied this workflow to ENL, a transcriptional regulator essential for certain acute leukemias. Thousands of chemically diversified analogs were generated from a known ENL binder, then screened for degradation activity using a sensitive cellular assay. One molecule emerged that not only triggered rapid ENL depletion but also demonstrated high selectivity, sparing unrelated proteins and markedly reducing leukemia cell proliferation. Mechanistic studies revealed a cooperative binding mode: the compound first engages ENL, reshaping its surface to recruit a specific ubiquitin ligase, thereby achieving precise proteasomal tagging.

Beyond the ENL case study, the methodology signals a paradigm shift for drug discovery. By making proximity‑inducing chemistry systematic, researchers can now explore vast chemical spaces with direct functional feedback, potentially unlocking therapeutic options for a wide array of diseases where traditional inhibition fails. Pharma pipelines are likely to incorporate such high‑throughput, cell‑based screens to expand the druggable proteome, accelerating the translation of molecular‑glue concepts into clinically viable treatments.